Protocolo Péptidos Request protocol →ES · EN
Research reference · 5 mg vial

Kisspeptin-10 dosage & reconstitution (5 mg vial)

Kisspeptin-10 dosage: calculations for a 5 mg vial use the same amounts described in the literature. Adding 1 mL of bacteriostatic water produces 5 mg/mL, so each U-100 unit contains 50 mcg.

Vial strength 5mg 10mg
01

Kisspeptin-10 Quick Reference (5 mg vial)

Vial contents5 mg Kisspeptin-10
Final volume1 mL
Concentration5 mg/mL
One U-100 unit50 mcg in 0.01 mL
Kisspeptin-10 5mg

Research context: mechanisms, human and preclinical evidence, limitations and precautions are in How this works and References. The calculator (Spanish) converts any other volume.

02

Kisspeptin-10 Dosage Chart (5 mg vial)

Dosing & Reconstitution Guide

Educational guide for reconstitution and daily dosing

Standard / Gradual Approach (1 mL = ~5 mg/mL)

Week / phaseDaily doseUnits per injection (mL)
Weeks 1–2100 mcg2 units (0.02 mL)
Weeks 3–8 (or 3–12)200 mcg4 units (0.04 mL)

Frequency: Once daily, subcutaneously, at a consistent time.

Reconstitution Steps

  1. Draw 1 mL of bacteriostatic water with a sterile syringe.1
  2. Inject slowly down the vial wall; avoid shaking to prevent foaming.2
  3. Gently swirl or roll until fully dissolved (clear solution).3
  4. Label with the reconstitution date and refrigerate at 2–8 °C, protected from light; use within 4 weeks.4

The per-phase amounts are identical across the Kisspeptin-10 family. The 5 mg vial only changes the concentration, U-100 units, volume and supplies.

Important: this guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

U-100 Conversion Table (1 mL = 5 mg/mL)

U-100 unitsVolumeContainsYield per vial
20.02 mL100 mcg50 injections
50.05 mL250 mcg20 injections
100.10 mL500 mcg10 injections
200.20 mL1 mg (1000 mcg)5 injections
300.30 mL1.5 mg (1500 mcg)3 injections
500.50 mL2.5 mg (2500 mcg)2 injections
1001.00 mL5 mg (5000 mcg)1 injection
03

Supplies Needed

Straightforward 12- and 24-week planning for a 5 mg vial at 5 mg/mL.

Kisspeptin-10 vials (5 mg each)

  • Standard / Gradual Approach, 12 weeks: Minimum 4 vials (15.4 mg required).
  • Standard / Gradual Approach, 24 weeks: Minimum 7 vials (32.2 mg required).

U-100 syringes (1 mL)

  • Standard / Gradual Approach, 12 weeks: 84 new syringes for 84 injections.
  • Standard / Gradual Approach, 24 weeks: 168 new syringes for 168 injections.

Bacteriostatic water

  • Standard / Gradual Approach, 12 weeks: 4 mL total (1 mL per vial) → 2 × 3 mL vials.
  • Standard / Gradual Approach, 24 weeks: 7 mL total (1 mL per vial) → 3 × 3 mL vials.

Alcohol swabs

  • Standard / Gradual Approach, 12 weeks: 168 minimum; one box of 100 does not cover the calculation.
  • Standard / Gradual Approach, 24 weeks: 336 minimum; one box of 100 does not cover the calculation.

Sharps container: one appropriately sized. Stability planning: totals are minimum arithmetic quantities; follow the product documentation for sterility, storage, handling loss and discard timing.

Kisspeptin-10 5mgView in store
U-100 syringes (1 mL)1 mL, fine needle
Bacteriostatic water 3 mLView in store
Alcohol swabs70 % isopropyl

Store links may earn a commission. A supplier page is not scientific evidence or proof of suitability for human use.

04

Kisspeptin-10 Vial and Research Context

  • Reconstitute: add 1 mL of bacteriostatic water to produce 5 mg/mL.
  • Frequency in the source: once daily, subcutaneously.
  • Described range: schedules run from 100 mcg to 200 mcg per injection.
  • Easy measuring: 1 U-100 unit = 0.01 mL = 50 mcg.
  • Vial size: the 5 mg label is total nominal content, not a per-injection amount.
  • Vial coverage: at 100 mcg per injection one vial supplies 50 injections; at 200 mcg it supplies 25. These are mass calculations, not storage periods.
05

Protocol Overview

Quick reference for the schedules shared by the cited literature.

  • Frequency: once daily.
  • Concentration: 5 mg in 1 mL = 5 mg/mL.
  • Unit conversion: 1 U-100 unit = 50 mcg.
06

Dosing Schedule

The tables keep each approach separate.

  • Standard / Gradual Approach: 100 mcg, 200 mcg, in phases (once daily).
  • Measurement: use the units and mL shown beside each amount.
  • Consistency: vial size does not change the schedule.
07

Storage Instructions

  • Lyophilized (unopened): −20 °C for long-term storage; 2–8 °C if used within weeks. Protected from light.
  • Reconstituted: 2–8 °C, do not freeze. Use within the documented period (typically up to 4 weeks with bacteriostatic water).
  • Handling: do not shake; avoid temperature cycling; label with date and concentration.
  • Discard: cloudy solutions, particulates or expired preparations are discarded.

More detail in the storage guide (Spanish).

08

Important Notes

  • Research only: the referenced compounds are sold for laboratory research. Nothing here is medical advice or an administration schedule.
  • Above 100 units: a 1 mL U-100 syringe cannot hold them; split across syringes or reconstitute with less volume.
  • Accuracy: concentration depends on the actual volume added; measure the diluent with a syringe, not by eye.
  • Verification: confirm vial contents against the batch certificate of analysis before calculating.
09

How This Works

  • Activación de neuronas GnRH: Kisspeptin binds KISS1R on GnRH-producing hypothalamic neurons, stimulating their pulsatile release
  • Cascada gonadal: GnRH liberado activa hipófisis → LH y FSH → testículos u ovarios → testosterona, estrógeno, progesterona
  • Restoration of the physiological axis: unlike exogenous TRT, kisspeptin works with the natural system, preserving pulsatile architecture
  • Pulsatilidad mantenida: a critical mechanism for avoiding desensitization of the axis
10

Research Applications

  • Functional hypogonadotropic hypogonadism
  • Gonadal axis recovery after anabolic steroid use
  • Investigaciones en infertilidad masculina y femenina
  • Pubertad retrasada constitucional
  • Hypogonadism associated with obesity or chronic stress
  • Endogenous testosterone support in simultaneous use with other peptides
11

Precautions Described in the Literature

Benign profile in research. Do not combine with exogenous TRT (defeats the purpose of the peptide). Monitor LH, FSH, total and free testosterone, and estradiol during the protocol. Relative contraindications: active hormone-dependent cancers.

12

Studied Combinations

  • Kisspeptin + HCG for full gonadal axis recovery
  • Kisspeptin + CJC No DAC + Ipamorelin para soporte hormonal integral
13

Injection Technique in Research

  • Route in the studies: subcutaneous, in abdominal or thigh adipose tissue, rotating the site.
  • Syringe: 1 mL U-100 (100 units); read in units, not mL.
  • Asepsis: alcohol swab on the stopper and the site; a new syringe per injection.
  • Drawing: purge air, draw the units from the chart and verify before withdrawing the needle from the vial.

Full guide: U-100 syringes and reading units (Spanish).

14

Research Note

All content on this page is technical and educational. It describes how a vial is reconstituted, how a syringe is read and which amounts the cited sources describe. It does not replace the supervision of a qualified researcher or the judgment of a health professional, and it is not intended to diagnose, treat, cure or prevent any disease.

15

References

  1. Seminara SB, Messager S, Chatzidaki EE, et al. The GPR54 gene as a regulator of puberty. N Engl J Med. 2003;349(17):1614-1627.
  2. Dhillo WS, Chaudhri OB, Patterson M, et al. Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males. J Clin Endocrinol Metab. 2005;90(12):6609-6615.
  3. George JT, Veldhuis JD, Roseweir AK, et al. Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men. J Clin Endocrinol Metab. 2011;96(8):E1228-1236.
16

Related Protocols

Research material only. Technical and educational content. Not medical advice, an administration schedule or a recommendation for use, and not intended to diagnose, treat, cure or prevent any disease. The referenced compounds are sold for laboratory research.

This site is an independent publication. Supplier links may earn a commission.